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ABSTRACT:  The mechanism underlying a sustained blood pressure elevation and its sequelae on the inflammatory 
cascades have not been totally unraveled. This research was, in addition to body mass index (BMI), systolic and diastolic 
blood pressure (SBP and DBP) therefore, primarily set to assess the levels of; interleukins -18 and 10 (Il-18 and Il-10) as 
markers of pro and  anti-inflammation. The study included 317 subjects-100 untreated with essential hypertension and 
currently not on drugs, 114 with essential hypertension and on antihypertensive drugs together with DASH diets and 
lifestyle modifications. The remaining were 103 control subjects with normal blood pressure. All parameters were assessed 
in treated and untreated hypertensive patients relative to apparently healthy subjects. Secondarily, it was also designed to 
assess the effect of treatment, gender and age on all estimated parameters. The results were subjected to statistical analysis 
using SPSS 21. The Student’s t test was used in comparing means. Values were Significant at P<0.05. SBP, DBP, Il-18, 
were significantly increased while IL10 was significantly decreased in both treated and untreated hypertensive compared 
to control. BMI was insignificantly increased in treated hypertensive but significantly increased in untreated hypertensive 
relative to control. SBP, DBP, Il 18, were significantly lower while IL10 was significantly higher in treated hypertensive 
compared with untreated hypertensive. It was discovered that inflammation is a hallmark in hypertensive can be 
significantly reversed through the administration of antihypertensive drugs, diets and a strict adherence to healthy lifestyle 
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Hypertension or high blood pressure is a global 
problem that affects approximately 15-20% of all 
adults (Wang et al., 2008). Hypertension is known as 
the silent killer as it shows no signs and symptoms. 
Even though it is simple to diagnose and usually can 
be controlled by healthy diet, regular exercise, 
medications or a combination of these, hypertension if 
unattended to will cause grave manifestations (Yeh et 
al., 2009). Hypertension is associated with 
cardiovascular disease, insulin resistance, 
carbohydrate intolerance, hyperuricaemia and 
atherosclerosis (Yeh et al., 2009). It also affects the 
structures and functions of small vascular arteries, 
arterioles and other blood vessels and can cause 
damage at variable rate to various target organs 
including kidney, brain and eye, related with the end 
stage of renal disease and to be the cause of stroke 
(Escobales et al., 2005; Lee et al., 2010). It is 
associated with the alterations in the blood vessels 
wall that is affecting the endothelium, the media and 
the adventitia; the alteration in the media leads to 
remodelling of the vessel wall (Escobales et al., 2005). 
Patients with hypertension may die prematurely with 
the most common cause of death being heart disease, 
while strokes and renal failures are also frequent, 
particularly in those with significant retinopathy (Lee 
et al., 2010). 
 
Interleukin -18 is a pleiotropic pro-inflammatory 
cytokine and plays a central role in the inflammatory 
cascade (Dinarello and Fantuzzi, 2003). Cells known 
to express interleukin 18 include macrophages, 
Kupffer cells, keratinocytes, and glucocorticoids-
secreting adrenal cortex cells (Blankenberg et al., 
2002). It is a member of the interleukin 1 super family, 
has several biological activities that initiate and 
promote host defence and inflammation (Dinarello 
and Fantuzzi, 2003). It is biologically and structurally 
related to interleukin 1 beta (Dinarello and Fantuzzi, 
2003). In contrast to most other cytokines, but in a 
similar way to IL-1b, IL-18 is expressed as a 
precursor, pro-IL18, which is not active until cleaved 
by the enzyme caspase-1. Caspase-1 itself exists as an 
inactive precursor which requires the assembly of 
multi-unit complexes, known as inflammasomes, to be 
activated (Nakanishi et al., 2001). Experimental 
research have shown that interleukin 18 enhances 
atherosclerosis through release of interferon gamma 
(Whitman et al., 2002) and induces expression of 
inflammatory cytokine IL-6 in the vascular endothelial 
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and smooth muscle cells (Gerdes et al., 2002).These 
downstream cytokines are associated with highly pro 
inflammatory T-helper 1 (Th1)- and T-helper 17 
(Th17)-type immune responses and there is evidence 
to suggest that Th1 and Th17 cells play a major role in 
hypertension It has been proposed that the vascular 
systemic inflammation produced by adipose tissues 
contributes to the development of hypertension 
(Dinarello and Fantuzzi., 2003). Interleukin 18 
provides powerful information on future fatal 
cardiovascular events across the entire spectrum of 
patients with stable coronary artery disease (CAD) and 
patients with unstable CAD (Blankenberg et al., 
2002). IL-10 on the other hand is an anti-inflammatory 
cytokine that is produced by activated T cells, B cells, 
keratinocytes, and monocytes (Howard et al., 1992). 
Interleukin 10 (IL-10) is a Type II cytokine in a family 
that includes: IL19, IL-20, IL-22, IL-26, and IL-29.  
 
These cytokines have similar gene organisation and 
bind to receptors of similar structure (Akuffo et al., 
1999). In general, the main biological functions of IL-
10 are to decrease or regulate the inflammatory 
response produced by dendritic cells and macrophage 
(Akuffo et al., 1999). Surprisingly, IL-10 is not always 
inhibitory, it can also promote B-cell activation and 
stimulate NK-cell proliferation. When IL-10 is 
produced and secreted, it acts specifically on the IL-10 
receptor, the structure of which consists of two 
subunits; IL-10 receptor 1 and IL-10 receptor 2. IL-10 
is highly secreted in mucosal tissues, such as the gut 
and the lung, where unwanted or uncontrolled immune 
responses can be very damaging (Pestka et al., 2004).  
 
As hypertension has been described to be a 
manifestation of immunological and other factors 
(Aristides and Rayaz, 2007), this research was, in 
addition to body mass index (BMI), systolic and 
diastolic blood pressure (SBP and DBP) therefore, 
primarily set to assess the levels of interleukins 10 and 
18  (Il- 10 and18) as  anti and pro inflammatory 
markers in treated and untreated hypertensive patients 
relative to apparently healthy subjects. 
 
MATERIALS AND METHODS 
Study Design: A cross-sectional design using a 
stratified random sampling method was used. 
Stratification was by age and therapy. 
 
Study Area The study area is Ado Ekiti and its 
immediate environs. 
 
Sample Size. The minimum sample size (N) was 
calculated to be 308 by single proportion formula, 








Where; Z= confidence level at 95%, N=Minimum 
sample size, D= desired precision=0.05, P= estimated 
prevalence of essential hypertension in Ado-Ekiti. 
Thus,  
 





Therefore to make up for possible drop outs and 
outliers, a total of three hundred and seventeen (317) 
subjects were investigated. 
 
Inclusion And Exclusion Criteria: Men and women 
who are hypertensive whether on therapy or not 
partook in the study. Inclusion was based on the cut-
off of at least 140mmHg systolic and or 90 mmHg 
diastolic Blood pressure while Subjects below the age 
of 18 years, pregnant women, nursing mothers, 
diabetes mellitus subject, chronic kidney disease, and 
sufferers of other disease conditions were excluded. 
 
Grouping: Treated hypertensives are those that have 
been diagnosed of Hypertension and have been on 
treatment for at least 3months. Treatment being the 
administration of antihypertensive drugs alongside 
DASH diets and lifestyle modifications. Untreated 
hypertensives are those that have just been newly 
diagnosed of having essential hypertension or a known 
hypertensive that have not been on treatment for at 
least 3 months. Ethical approval was sought for, from 
Afe Babalola University Teaching Hospital, Ado 
Ekiti, Ekiti state.  
 
Sample Collection: Venous blood sample of about 5ml 
was collected from the cubital fossa using a 22G 
needle and syringe and dispensed into a plain bottle 
(non-anticoagulant bottle). The blood was allowed to 
clot and centrifuged at 12000rpm for 5 minutes to 
separate the serum from cells.  The serum samples 
were stored at temperature of -20 degree Celsius for a 
maximum of 5 days before assayed for interleukins 10 
and 18. 
 
Determination of Basal metabolic rate (BMI): 
Anthropometric data which include body weight and 
height were obtained using bathroom scales and a 
height gauge respectively. The height (m) and weight 
(Kg) measurements were then used to calculate the 
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Determination of Blood pressure (Systolic and 
diastolic) readings was taken from the non-dominant 
arm using a digital sphygmomanometer (Omros, 
Japan) according to manufacturer’s guidelines. 
Systolic blood pressure (SBP) and diastolic blood 
pressure (DBP) were displayed digitally. 
 
Procedures and quality control measures for blood 
pressure determination:  Before taking measurements: 
i. The subjects were instructed to abstain from 
exercise, smoke or consumption of foods or 
drinks containing caffeine (such as tea or coffee) 
for at least 30 minutes before measurement 
ii. ii. The subjects were made to wear loose-fitting 
and comfortable clothes,  
iii. Rest and relax for 5 minutes without any 
distractions (such as watching television). 
iv. A stable table and chair of appropriate height was 
chosen 
v. The subject were comfortably seated and relaxed 
with their back supported  
vi. The arm was supported on a tabletop at an even 
level with your heart 
vii. The  feet were on the floor and it was made sure 
that the legs were not crossed 
 
Measuring Blood Pressure: 
i. The sleeve was rolled up to expose the upper arm 
and the cuff was wrapped around it  
 ii. The cuff on the exposed arm was placed 2cm 
(approximately two finger-breadths) above the elbow. 
iii The tubing was placed at the centre of the arm 
facing the front, the sensor was correctly placed and 
the end of the cuff was pulled so that it was wrapped 
evenly and firmly around the arm. 
iv It was checked that the tightness of the cuff is 
appropriate so that when the cuff inflates it should not 
cause any painful sensation   
v. Once the start button is pressed the cuff inflates to a 
maximum, then automatically slowly deflate. Once the 
measurement is completed, readings of the systolic 
and diastolic blood pressure were displayed on the 
digital panel  
vi. The reading of each measurement was then 
recorded 
vii. After completing each measurement, the cuff was 
released completely 
viii. Readings were taken in duplicates at an interval 
of at least one minute between readings  
ix. The average value of the two readings was 
calculated. This value is taken to be the diastolic blood 
pressure. In case of the two readings on a subject 
differing by more than 5 mmHg, one additional 
reading was obtained before the average was taken. 
c. Interleukins 18 and 10 were estimated using ELISA 
based kits.  
Assay procedure: 1. 100 μL of each standard and 
sample was added into appropriate wells.  The plate 
was covered well and Incubated for 2.5 hours at room 
temperature with gentle shaking. All materials and 
prepared reagents were equilibrated to room 
temperature (18- 25°C) prior to use. 
2. The Solution was discarded and washed 4 times 
with 1X Wash Solution. It was washed by filling each 
well with 1X Wash Solution (300 μL) autowasher. 
After the last wash, removal of any remaining Wash 
Buffer was done by aspiration. 
3. The 100μLof 1X Biotinylated IL-10 or 18 Detection 
Antibody was added to each well to each well. It was 
incubated for 1 hour at room temperature with gentle 
shaking. 
4. The solution was discarded. The wash as in step 2 
was repeated. 
5.100μL of 1X HRP-Streptavidin solution was added 
to each well and then incubated for 45 minutes at room 
temperature with gentle shaking. 
6. The solution was discarded .The wash step as in step 
2 was repeated. 
7.100 μL of TMB One-Step Substrate Reagent was 
added to each well and incubated for 30 minutes at 
room temperature in the dark with gentle shaking. 
8. 50 μL of Stop Solution was added to each well. The 
absorbance was read at 450nm wavelength 
immediately. The concentration of IL-10or 18 for each 
sample well was computed and displayed on the 
digital monitor. 
Statistical Analysis. Results obtained were subjected 
to statistical analysis using SPSS (version 21.0 
software, SPSS Inc. Chicago, Illinois, USA). All 
parameters were expressed as mean ± SD. The 
Student’s t test was the tool of choice in comparing 
means. Values were statistically significant at p≤ 0.05. 
 
RESULTS AND DISCUSSION 
Table 1.  Body mass index (BMI), Systolic and 
Diastolic blood pressure (SBP and DBP), Interleukin 
18 (Il 18), in treated hypertensive when compared with 
control (Table 4.1). BMI was insignificantly higher 
while blood pressure (SBP and DBP) Il 18 were 
significantly higher while Il10 was significantly lower 
in treated hypertensive compared with control. 
Hypertension (HTN) is a sustained elevation of resting 
systolic BP (≥ 120mm Hg), diastolic BP (≥90 mm Hg), 
or both (AHA, 2014). Essential hypertension is the 
result of a complex interplay between multiple 
regulatory systems which are themselves influenced 
by a multitude of genetic and environmental factors 
(McCallum et al., 2015), resulting in a sustained blood 
pressure elevation to which no specific cause can be 
adduced. The excessive high pressure on artery walls 
caused by HTN can damage blood vessels along with 
organ function. This increases the risk for developing 
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several health conditions including heart attack, 
stroke, chronic heart failure (CHF), and kidney disease 
(Saseen et al., 2014).  
 
Table 1 BMI, blood pressure, Il 18 and Il 10 in treated hypertensive 
compared with control 
 
 
Table 2 BMI, blood pressure, Il 18 and Il 10, in 
untreated hypertensive when compared with control. 
BMI, blood pressure and Il 18 were significantly 
higher while Il 10 was significantly lower in untreated 
hypertensive compared with control. 
 
Table 2 BMI, blood pressure, IL 18 and IL 10 in untreated 
hypertensive compared with control  
 
 
Table 3 BMI, blood pressure, Il 18, in treated 
compared with untreated hypertensive. BMI and Il 10 
was insignificantly lower while blood pressure (SBP 
and DBP), Il 18, in treated hypertensive were 
significantly higher when compared with control. 
  
Table 3. BMI was insignificantly higher, blood pressure, Il 18 and 
IL 10 in treated hypertensive compared with untreated hypertensive 
 
 
Figure 1 and 2. IL18 and IL10 levels according to age 
groups in untreated essential hypertensive. IL10 shows 
a pattern of reduction with advancement in age. While 
interleukin 18 shows a pattern of increase with 
advancement in age till the fifties, after then a nosedive 
in concentration. The Systolic blood pressure (SBP) is 
that due to the pumping of the heart while the diastolic 
blood pressure (DBP) is the measurement of force per 
unit area as the heart relaxes to allow the blood to flow 
into it (Mancia et al., 2013). In this research, the 
systolic and diastolic blood pressure in both treated 
and untreated hypertensive were found to be 
significantly higher than in control.  There was also a 
significant reduction in the SBP and DBP in treated 
hypertensive when compared with untreated 
hypertensive. This findings partially agree with the 
works of Svensson et al., (2004) where Systolic BP 
(SBP) was significantly higher in hypertensive 
patients on treatment as compared to controls but did 
not differ with regard to diastolic BP. It however 
totally agrees with the works of Diego et al., (2017) 
and Norbert et al., (2017).  
 
 




Fig 2. IL10 levels according to age groups in untreated essential 
hypertensive 
 
Probing Further, a more critical look at this finding 
shows that classical treatment with drugs, DASH diets 
and lifestyle modifications was able to bring both the 
diastolic and systolic blood pressure nearer towards 
the internationally accepted values seen in controls or, 
that treatment was effective enough to bring about the 
alleviation of a severe case to a moderate one. 
According to one review published in 2003, a 
reduction of the blood pressure by 5 mmHg can 
decrease the risk of stroke by 34%, of ischaemic heart 
disease by 21%, and reduce the likelihood 
of dementia, heart failure, and mortality  from 
cardiovascular diseases (Law et al., 2003). It should 
however be recalled that the essence of treatment is to 
close the gap in the levels of parameters seen in 
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Body mass index (BMI) is a measure of weight 
adjusted for height, calculated as weight in kilograms 
divided by the square of height in meters (kg/m2). In 
this research, the BMI in treated hypertensive was 
found to be insignificantly higher while that seen in 
untreated hypertensive was significantly higher when 
both were compared with that seen in control.  
Similarly, there was a insignificant variation when the 
BMI seen in untreated hypertensive was compared 
with that seen in treated hypertensive. This findings 
partially agrees with the works of Azantsa et al., 
(2010); Zhang et al., (2016) and Norbert et al., 2017, 
where body mass index was seen to be significantly 
higher in hypertensive, whether treated or untreated, 
when compared to control. As being overweight has 
been described as a risk factor for the development and 
progression of hypertension (Poulter et al., 2015), it 
would just be wise that weight shedding as a form of 
lifestyle change and medications will lower blood 
pressure and decrease the risk of health complications 
(NHLBI, 2015 )  
 
Interleukin 18 is described as a member of interleukin 
1 cytokine superfamily, it regulates innate and 
acquired immune response (Alastair et al., 2003). In a 
few words interleukin 18 is a common participant in 
the inflammation cascade and has been known to be 
pro inflammatory in nature. Serum interleukin 18 was 
significantly higher in treated and untreated 
hypertensive when compared with control. 
Furthermore, there was also a significant increase in 
untreated hypertensive when compared with treated 
hypertensive. This agrees with the works of hung et al. 
(2005) and Luc et al. (2013) where IL-18 and other pro 
inflammatory cytokines are significantly correlated 
with hypertension as there was a significant 
correlation between systolic blood pressure and serum 
interleukin-18 in both treated and untreated 
hypertensives. Rabkin in 2009 also elucidated on the 
role of interleukin 18 on the promotion of vascular 
abnormalties in hypertension. The pattern of increase 
in serum IL18 is consistent with advancement in age. 
Interleukin 10 (IL-10) is a potent anti-inflammatory 
cytokine that plays a crucial, and often essential, role 
in preventing inflammatory and autoimmune 
pathologies (Kuhn et al., 1993; Sabat et al., 2010).  In 
this research, it was seen that interleukin10 level was 
significantly lower in both treated and untreated 
hypertensives relative to control, a finding that 
supports the notion as stated by Lima et al. (2016) 
where IL10 was said to possess anti pressor activities 
in mice. It was also observed that IL10 was 
significantly lower in untreated when compared with 
treated hypertensive, bringing up a insinuation 
whether IL10 could be of benefit not only in diagnostic 
and prognostic but also in therapeutic terms. A pattern 
of decrease in interleukin 10 was seen with 
progression in age. There is a speculation to these 
findings, as IL10 is mostly, if not wholly anti-
inflammatory in action, Susceptibility to inflammation 
will be more likely in hypertensive and with 
advancement in age, hypertensive control in the 
elderly could be more difficult as a result of lower 
levels of down regulators of inflammation activation, 
such as interleukin10 (IL-10). There may therefore be 
unrestrained limit for inflammasomes drive for 
inflammation and consequent increased potential for 
structural damage. 
 
Conclusion: This research found out that accelerated 
inflammation could be an hallmark of hypertension 
but could likely be reversed by treatment, through 
lifestyle and diet modifications and antihypertensive 
drugs. Lastly, this research ventured into and 
discovered that the efficacy of treatment on 
hypertension is incontrovertible. It also confirmed that 
medication and dash diet could alleviate the 
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